COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Nordic HY-Markt verzeichnet Rekordhalbjahr 2025, internationale Nachfrage steigt weiter
Nordic HY-Market achieves record levels in H1 2025, driven by intense refinancing activity and growing international participation. Germany shows dynamic growth. Pareto Securities leads in DACH region -
-
COMMUNIQUÉ DE PRESSE
Inside Information / Other news releases
Adocia and Tonghua Dongbao announce positive Phase 3 results of Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in Type 2 Diabetes. Significant HbA1c reduction and improved post-meal blood glucose levels compared to Humalog® -
-
COMMUNIQUÉ DE PRESSE
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax annonce exercice intégral option souscription ADS supplémentaires. Produit brut Offre à 747,5 M$. Société biotechnologie spécialisée en immunothérapie. Prix offre 64,00$ par ADS. Actions admises Nasdaq et Euronext. Document relatif déposé auprès de la SEC -
COMMUNIQUÉ DE PRESSE
Rational AG: Continuity on the Executive Board – Markus Paschmann appointed to the Executive Board for Sales and Marketing for a further three years.
Rational AG extends Markus Paschmann's contract on the Executive Board for Sales and Marketing for another three years, emphasizing continuity and growth -
COMMUNIQUÉ DE PRESSE
Coinsilium Group Limited: Result of Substantially Oversubscribed WRAP Retail Offer
Coinsilium Group Limited confirms result of substantially oversubscribed WRAP Retail Offer raising £500,000 with 4 times demand. New Ordinary Shares issued at 6p/share. Total voting rights to be 487,234,495 upon Admission -
-
COMMUNIQUÉ DE PRESSE
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds
